Synergistic Effect Of Combination Of Chemotherapeutic Drugs For The Treatment Of Hepatocellular Carcinoma Savita Mishra, Kumud Bala and Deepshikha Pande Katare* Amity Institute Of Biotechnology, Amity University Uttar Pradesh, Noida * Corresponding Author: dpkatare@amity.edu Abstract Methodology Hepatocellular carcinoma (HCC), which is derived from well differentiated hepatocytes, is the predominant malignant tumor seen across the globe. However latest report on cancer stem cell (CSC) suggest that impaired signalling pathways has been involve in hepatocarcinogenesis. These signalling molecules and receptors can be considered as key for determination of HCC. The present study aimed to see the changed synergistic effect of combination of chemotherapeutic and herbal compound for the treatment of Hepatocellular carcinoma. In the present study an animal model of HCC was developed in the male Wistar rats and the drug combination was tested on it. We observed that marker enzyme showed reduced level of serum AST, ALT, bilirubin as compare to the diseased animal. In conclusion, combination therapy may leads to the new future for the liver cancer treatment. Development of animal model for liver cancer Treatment using Combination of Herbal and Synthetic drugs Diseased Wistar Rat Wistar Rat Single Daily dose of drug Combination DEN/AFF (200/150 mg per kg body weight) Treatment for 7 Days Selection Phase 3 month ANALYSIS ALT, AST and Bilirubin assay Total protein Content Proteomic analysis(SDS PAGE analysis) Weight Change analysis Introduction Result HCC involve many genetic alterations, that eventually, leads to malignant transformation of the hepatocytes. Impaired signaling pathways and its receptors such as transforming growth factor β (TGF-β), different notch receptors(NOTCH1, NOTCH2, NOTCH3, and NOTCH4), Wnt and Hedgehog pathways has been involve in hepatocarcinogenesis [Song et al., 2013, Lachenmayer, et al., 2012] Sorafenib, a FDA approved drug (a bi-aryl urea, MW: 464.83), is a Raf serine/threonine kinases inhibitor. Indeed several Herbal compounds like some flavonolignans, also share angioprevention properties. Combination of herbal (flavonolignans) and Synthetic drug (Sorafenib) can give new future in HCC treatment. Conclusion Sorafenib drug combination Shows following effect 1-D SDS PAGE analysis showed the differential expression of proteins of molecular weight 171KDa, 124KDa and 120KDa. Histopathological analysis shows significant change in Serum activities of ALT and AST in diseased animal exhibit significant increase but after treatment is shows notable decrease in ALT AST and Bilirubin level Weight got decrease with the treatment of drug combination as compare to disease References Lachenmayer A, et al. Cancer Res, 2012; 18 (18): 4997-5007 Connock M, et al. 2010 May;14 Suppl 1:17-21. PMID: 20507799 Shabnam Malik, Shilpa Bhatnagar, Naveen Chaudhary, Deepshikha Pande Katare & S. K. Jain. Protoplasma (2013) 250:175–183 Objectives To evaluate efficacy of drug combination using proteomic Biomarker To analyze biochemical changes using drug combination. To analyze weight change during treatment Acknowledgement Financial assistance to NMPB(Z.10817/187/CSS/R&D/UP-01/2010-11 NMPB)